Needham Reiterates Buy Rating on TransMedics Group (TMDX)

Needham analyst Mike Matson reiterated a Buy rating and $106.00 price target on TransMedics Group (NASDAQ: TMDX).

The analyst comments "After the market closed on Thursday, TMDX announced that it had appointed Fernando Araujo as CFO. Araujo has more than 20 years of experience in public company finance roles at GE Healthcare (GEHC - Not Covered), General Electric (GE - Not Covered), and 3M (MMM - Not Covered). His most recent role was CFO of GE HealthCare's Advanced Imaging Solutions, a $16B segment. Gerardo Hernandez, formerly CFO, will transition to Commercial Strategic Advisor, LATAM where he will lead TMDX's expansion into Latin America.

TMDX also reiterated guidance for 2026 revenue of $737-757M (22-25% growth) which excludes any contribution from the recent strategic investment in PAD Aviation Service GmbH. TMDX intends to revisit its outlook following the 3Q26 results.

We spoke with management following the announcement. They indicated that the CFO change was driven by increasing complexity in the business as TMDX expands outside the US. We believe that Araujo's diverse finance and international experience in large, multinational companies makes him well suited for TMDX's evolving business."

For an analyst ratings summary and ratings history on TransMedics Group click here. For more ratings news on TransMedics Group click here.

Shares of TransMedics Group closed at $85.04 yesterday.

You May Also Be Interested In

• Raymond James Starts Rocket Lab USA (RKLB) at Outperform
• Restoration Hardware (RH) PT Lowered to $190 at TD Cowen
• JPMorgan Upgrades SBI Shinsei Bank (8303:JP) (SKLKY) to Neutral